Summary ImmusanT Inc (ImmusanT) is a drug company that discovers and develops therapies for celiac disease. The company’s pipeline products include Nexvax 2 and Nexvax 3. Its pipeline product Nexvax 2 is used for treating, preventing and diagnosing celiac disease. ImmusanT’s pipeline products are also used for the treatment of diabetes, thyroid autoimmunity, autoimmune liver diseases, rheumatoid arthritis and allergies with defined peptides such as peanut allergy. The company’s treatment for celiac disease is an immune tolerizing therapy that uses a series of peptides that target the common genetics in the disease. It also offers clinical trial services. ImmusanT is headquartered in Cambridge, Massachusetts, the US. ImmusanT Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals... Research Beam Model: Research Beam Product ID: 1995983 250 USD New
ImmusanT Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
 
 

ImmusanT Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • Category : Company Profiles
  • Published On : August   2017
  • Pages : 25
  • Publisher : GlobalData
 
 
 
Summary

ImmusanT Inc (ImmusanT) is a drug company that discovers and develops therapies for celiac disease. The company’s pipeline products include Nexvax 2 and Nexvax 3. Its pipeline product Nexvax 2 is used for treating, preventing and diagnosing celiac disease. ImmusanT’s pipeline products are also used for the treatment of diabetes, thyroid autoimmunity, autoimmune liver diseases, rheumatoid arthritis and allergies with defined peptides such as peanut allergy. The company’s treatment for celiac disease is an immune tolerizing therapy that uses a series of peptides that target the common genetics in the disease. It also offers clinical trial services. ImmusanT is headquartered in Cambridge, Massachusetts, the US.

ImmusanT Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
ImmusanT Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
ImmusanT Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
ImmusanT Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
ImmusanT Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
ImmusanT Inc, Medical Devices Deals, 2011 to YTD 2017 9
ImmusanT Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
ImmusanT Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
ImmusanT Acquires A Discovery Platform From Nexpep 11
Venture Financing 12
ImmusanT Raises USD12 Million Series B Venture Financing 12
ImmusanT Secures US$20 Million In Series A Round Of Financing 13
ImmusanT Secures Seed Financing 14
Partnerships 15
ImmusanT Enters Into Research Agreement With Walter and Eliza Hall Institute of Medical Research 15
ImmusanT Inc - Key Competitors 16
ImmusanT Inc - Key Employees 17
ImmusanT Inc - Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Product News 19
05/19/2016: ImmusanT Announces Presentations at Digestive Disease Week 2016 19
05/08/2017: ImmusanT Reports Data on Novel Celiac Disease Diagnostic Approach 21
Clinical Trials 22
May 12, 2017: ImmusanT Announces Publication of Positive Data from Phase 1 Trials of Nexvax2 in Celiac Disease Patients 22
Feb 22, 2017: ImmusanT Announces Completion of Phase 1b Clinical Trial of Nexvax2 for the Treatment of Celiac Disease 23
May 24, 2016: ImmusanT Reports Nexvax2 Phase 1 Data in Patients with Celiac Disease 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
ImmusanT Inc, Pharmaceuticals & Healthcare, Key Facts 2
ImmusanT Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
ImmusanT Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
ImmusanT Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
ImmusanT Inc, Deals By Therapy Area, 2011 to YTD 2017 8
ImmusanT Inc, Medical Devices Deals, 2011 to YTD 2017 9
ImmusanT Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
ImmusanT Acquires A Discovery Platform From Nexpep 11
ImmusanT Raises USD12 Million Series B Venture Financing 12
ImmusanT Secures US$20 Million In Series A Round Of Financing 13
ImmusanT Secures Seed Financing 14
ImmusanT Enters Into Research Agreement With Walter and Eliza Hall Institute of Medical Research 15
ImmusanT Inc, Key Competitors 16
ImmusanT Inc, Key Employees 17
List of Figures
ImmusanT Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
ImmusanT Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
ImmusanT Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
ImmusanT Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
ImmusanT Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
ImmusanT Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
ImmusanT Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
ImmusanT Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
ImmusanT Inc, Medical Devices Deals, 2011 to YTD 2017 9
PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter